Thomas Roberts
Research Fellow / Group Leader
Tom Roberts studied at the University of Oxford for both his undergraduate degree in Molecular and Cellular Biochemistry and doctoral thesis titled 'Duchenne Muscular Dystrophy: RNA-based therapeutics and microRNA biology' in the Department of Physiology, Anatomy and Genetics in the laboratory of Professor Matthew Wood. He subsequently moved to San Diego, California where he undertook postdoctoral training positions at the Scripps Research Institute, Department of Molecular and Experimental Medicine (laboratory of Professors Kevin Morris and Marc Weinberg) and Sanford Burnham Prebys Medical Discovery Institute, Development, Aging and Regeneration Program (laboratory of Professor Lorenzo Puri). He returned to the University of Oxford, Department of Paediatrics in 2019 where he re-joined the Wood group.
He now leads a research group at the Institute of Development and Regenerative Medicine with the overall theme of 'RNA Medicine'. His research interests include neuromuscular disorders, RNA biology, extracellular nucleic acids, biomarkers, epigenetics, and gene/oligonucleotide therapies.
Recent publications
-
An extracellular vesicle delivery platform based on the PTTG1IP protein
Journal article
Martin Perez C. et al, (2024), Extracellular Vesicle, 4, 100054 - 100054
-
uORF-targeting steric block antisense oligonucleotides do not reproducibly increase RNASEH1 expression
Journal article
Ahlskog N. et al, (2024), Molecular Therapy - Nucleic Acids, 102406 - 102406
-
uORF-targeting steric block antisense oligonucleotides do not reproducibly activate RNASEH1 expression
Preprint
Ahlskog N. et al, (2024)
-
Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications
Journal article
Roberts TC., (2023), Molecular Therapy Methods and Clinical Development, 31
-
EV-mediated promotion of myogenic differentiation is dependent on dose, collection medium, and isolation method
Journal article
Hanson B. et al, (2023), Molecular Therapy - Nucleic Acids, 33, 511 - 528